Pre-clinical data published in Nature Communications (2025) · View Study
VeloxDX is developing a rapid diagnostic platform designed to detect urinary biomarkers associated with the most common UTI-causing bacteria.
Designed for use alongside clinical judgment and existing standards of care.
Today's UTI diagnostic pathway forces clinicians to choose between speed and accuracy. VeloxDX changes the equation.
Rapid biomarker detection is designed to support more targeted treatment decisions during the visit, rather than days later.
Earlier pathogen-associated information may help reduce unnecessary empiric antibiotic use and support antimicrobial stewardship goals.
In selected workflows, near-patient rule-in testing could reduce unnecessary culture volume and improve resource allocation.
Cultures take days. Treatment can't wait. That gap is where antimicrobial resistance is built.
Statistics are illustrative and based on published literature. Actual figures may vary by region and population.
VeloxDX is built around agmatine, a urinary biomarker associated with Enterobacterales infections, the group responsible for most bacterial UTIs.
Unlike dipsticks that infer infection indirectly, our approach is designed to detect pathogen-associated chemistry directly in urine.
The platform combines this biomarker strategy with electrochemical sensing in a disposable test format intended for near-patient use.
Our goal is to bring faster, more specific rule-in information to clinics, pharmacies, and primary care settings without requiring centralized lab infrastructure.
VeloxDX is committed to scientific rigor, clinical relevance, and regulatory transparency. We share our progress with the research community as we advance.
Chan, Gregson, Wildman et al. (2025) reported agmatine as a predictive urinary metabolite for culture-positive UTI specimens, with validation across blinded patient cohorts.
View PublicationPublished data reflect biomarker assay performance in the reported study cohorts and should not be interpreted as a complete substitute for standard microbiology in all clinical contexts.
We're actively engaging with investors, strategic partners, and clinical collaborators. We look forward to hearing from you and sharing more.
info@veloxdx.com